1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
HLB Co., Ltd.

HLB Co., Ltd.

KKRX:028300
41,300.00
KRW
-1,050.00
(-2.48%)
-1,573.28EPS
6.72TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
337.53
561.44
457.51
333.1
251.78
379.06
333.16
238.14
580.72
1,471.53
353.87
521.42
641.31
646.33
Basic EPS, GAAP
-138.61
-44.25
150.36
-146.05
-180.9
265.47
-384.9
-339.52
-816.08
-640
-1,547
-704
-1,680
-1,473.92
Free Cash Flow per Basic Share
-86.77
-91.78
-33.84
-138.95
-231.44
-312.61
-438.24
-557.41
-506.54
-609.57
-979.03
-1,082.1
-839.02
-747.59
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.35
- -
- -
- -
- -
- -
- -
Book Value per Share
257.25
336.91
970.5
973.81
833.37
1,750.42
1,697.73
4,013.33
3,620.07
5,222.6
4,235.07
4,396.88
3,149.21
3,122.7
Tangible Book Value per Share
248.62
326.47
-527.6
-463.88
-532.85
411.67
471.37
1,806.14
800.63
2,399.99
2,199.79
2,014.32
638.27
502.22
Basic Weighted Avg Shares
62
66
84
90
91
95
115
236
120
122
121
131
131
132
Sales/Revenue/Turnover
20,808
37,186
38,461
30,139
23,007
36,186
38,421
56,177
69,826
179,708
42,901
68,126
84,173
85,198
Operating Margin (%)
-25.71
0.97
-15.5
-69.69
-113.51
-81.01
-125.65
-109.14
-142.95
-41.55
-270.29
-173.75
-117.16
-109.22
Depreciation Expense
2,259
1,824
1,754
1,600
1,627
1,369
2,175
10,490
12,038
16,326
9,683
6,228
5,358
5,745
Net Income, GAAP
-8,545
-2,931
12,640
-13,215
-16,530
25,343
-44,386
-80,093
-98,125
-78,159
-187,547
-91,980
-220,501
-194,289
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-41.07
-7.88
32.86
-43.85
-71.85
70.04
-115.53
-142.57
-140.53
-43.49
-437.17
-135.02
-261.96
-228.05
Working Capital
719
12,156
5,461
11,688
-7,009
96,209
1,980
153,546
66,322
143,245
58,074
11,563
-223,385
-252,752
LT Debt
1,797
8,405
5,374
6,056
4,320
31,555
75,451
9,346
57,111
13,682
31,794
58,788
74,652
67,463
Total Equity
15,502
23,020
114,390
124,073
113,679
209,524
189,242
557,429
512,185
698,978
615,312
652,114
494,414
493,871
Return on Invested Capital (%)
- -
- -
-6.67
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
19.31
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-47.51
-14.61
23.27
-15.24
-19.92
20.12
-24.69
-24.1
-21.43
-14.56
-31.57
-16.33
-44.32
-41.83

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
119,372
210,293
202,078
LT Borrowings
38,749
58,224
51,109
LT Finance Leases
12,703
16,428
16,353
Preferred Equity and Hybrid Capital
4
4
4
Shares Outstanding
131
133
133
Market Capitalization
4,978,966
6,750,091
6,723,516

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
120,655
124,277
95,894
Cash, Cash Equivalents & STI
47,996
87,776
56,667
Accounts Receivable, Net
9,415
9,520
9,977
Inventories
14,894
9,454
11,001
Total Current Liabilities
184,328
347,662
348,647
Payables & Accruals
- -
- -
- -
ST Debt
119,372
210,293
202,078
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.75%
-0.36%
-24.18%
Free Cash Flow
70.58%
5%
-22.11%
Net Income, GAAP
-39.66%
46.18%
139.73%
Sales/Revenue/Turnover
25.23%
37.58%
23.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,154
14,794
16,953
25,225
68,126
2025
17,664
15,732
22,111
28,665
84,173
2026
18,689
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
247
-795
31
-191.74
-704
2025
-490
-440
-557
-193.07
-1,680
2026
-286
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hong-Cheol Kim
Full Time Employees
151
Sector
Health technology
Industry
Biotechnology
Address
216-53, Dangwol-ro Sejong-si SE South Korea 45011
IPO Date
Jul 27, 1996
Website
hlbkorea.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber reinforced plastic (GRP) pipes in South Korea and internationally; engages in the repair, inspection, fabrication, and installation of lifeboats and pipes; develops and manufactures biopharmaceutical products such as anti-cancer drugs including Rivoceranib; produces and sells medical devices, quasi-drugs including alcohol swabs and sampling tools, in-vitro diagnostics using nanoparticles like graphene and carbon nanotubes, and femtech products such as feminine cleansers, wipes, pregnancy testers, ovulation testers, vaginitis test kits, and urethritis test kits; and participates in e-commerce, investment, and financing activities. Founded in 1975 and headquartered in Ulsan, South Korea, the company operates primarily in the biotechnology, healthcare, and marine composite materials sectors, serving shipbuilders, pharmaceutical markets, medical facilities, and consumer health customers across domestic and global markets. In September 2025, HLB Co., Ltd. agreed to acquire HLB Science Inc. from HLB Global Co., Ltd. and others for KRW 30.9 billion through a merger, involving issuance of 0.8 million common shares at a swap ratio of 0.044632 per HLB Science share to consolidate healthcare operations; additionally, in November 2025, HLB Group, which includes the company, hosted its first Pitch Day event under the HLB New Wave open innovation initiative to foster collaborations with promising bio firms in areas like funding, R&D, and commercialization.